By Jonathan Gardner | Published October 8, 2026
In a move designed to fortify its position in the non-opioid pain management market, Viatris has announced the acquisition of two flagship assets from Pacira Biosciences. The deal, which brings the post-surgical pain treatment Exparel and the osteoarthritis knee-pain therapy Zilretta under the Viatris umbrella, represents a calculated bet on the durability of established pharmaceutical brands. Together, these assets generated nearly $700 million in revenue in 2025, providing Viatris with an immediate, high-margin revenue stream as it navigates a shifting landscape in the pharmaceutical industry.
Main Facts: The Strategic Rationale
The acquisition is the latest chapter in Viatris’s overarching corporate strategy, which focuses on the acquisition of high-value, on-market commercial assets rather than high-risk, early-stage drug development. By integrating Exparel and Zilretta into a portfolio that already includes staples like Celebrex and Relpax, Viatris is positioning itself as a dominant player in the non-opioid pain sector.
For Viatris, the primary goal is the optimization of these assets through its global supply chain and intellectual property expertise. As analysts at Leerink Partners have noted, the transaction is expected to be "immediately accretive" to revenue, providing a stable foundation for earnings growth that extends well into the 2030s. The acquisition allows Viatris to leverage its massive commercial infrastructure to expand the reach of these drugs, particularly in hospital settings where adoption has historically been a challenge.
Chronology: A Path to Consolidation
The road to this acquisition has been marked by years of legal maneuvering and market development by Pacira:
- 2024: Pacira secured critical manufacturing patents for Exparel, effectively extending the intellectual property protections for the drug until 2044. This move was pivotal in stabilizing the asset’s long-term outlook, though it remains subject to ongoing legal challenges from other generic manufacturers.
- 2025: Exparel and Zilretta combined to record nearly $700 million in annual sales, cementing their status as reliable revenue generators for Pacira.
- September 2026: Leerink analyst Daniel Clark initiated coverage on Pacira, highlighting that while Exparel’s growth had been previously constrained by hospital formulary restrictions, recent coverage wins—notably from UnitedHealthcare—had shifted the growth narrative.
- October 8, 2026: Viatris officially announced the acquisition of the Pacira assets, marking a significant consolidation in the pain management segment.
- December 27, 2026: The industry awaits the FDA’s decision on Viatris’s own fast-acting version of meloxicam, a move that would further broaden the company’s pain management capabilities.
Supporting Data: The Economics of the Deal
The financial logic behind the acquisition rests on the balance between current cash flow and future patent cliffs.
Exparel, a long-acting liposomal formulation of bupivacaine, has been a staple in post-surgical care. While it has faced competition, its utility in reducing the reliance on opioids has made it a preferred choice for many surgeons. However, the market for Exparel is not without its threats. Pacira’s previous patent settlements with Fresenius Kabi and a subsidiary of Hengrui Pharma created a roadmap for generic entry. These agreements allow the generic manufacturers to begin marketing "high single-digit" percentages of U.S. volume, with that share expected to scale toward 30% over the next three years.
Zilretta, an extended-release formulation of triamcinolone, faces a more definitive timeline. Its primary patent protections are slated to expire in 2031. Viatris is betting that its ability to manage these product lifecycles will allow it to sustain meaningful sales even as these drugs approach their respective patent expirations.
The following table summarizes the key asset profiles:
| Asset | Indication | Primary Patent Expiry | Market Position |
|---|---|---|---|
| Exparel | Post-surgical pain | 2044 (pending challenges) | Market leader, high volume |
| Zilretta | Osteoarthritis knee pain | 2031 | Niche, steady growth |
Official Responses and Corporate Strategy
Viatris has been vocal about its philosophy regarding the integration of these products. In a statement released Thursday, the company emphasized that it "plans to leverage its intellectual property expertise and proven ability to extend product lifecycles and sustain meaningful sales" even after generic competitors enter the market.
This approach reflects Viatris’s unique positioning in the pharma ecosystem. Unlike pure-play biotech firms that live or die by the success of a single molecule, Viatris operates on a model of scale and operational efficiency. By acquiring assets that have already passed the "valley of death"—the risky period of R&D and initial market approval—Viatris minimizes its exposure to clinical trial failure while maximizing the value of existing intellectual property.
"We do not anticipate a meaningfully different near-term trajectory for these assets," noted Daniel Clark of Leerink. "However, we like that Viatris is executing against its capital deployment strategy and adding what should be steady sources of growth and margin expansion into the 2030s."
Implications: The Future of Pain Management
The acquisition has broader implications for the pharmaceutical sector. As the industry faces increased pressure from the FDA and public health organizations to reduce the reliance on opioids for acute pain management, non-opioid alternatives like Exparel are becoming increasingly essential.
1. Market Concentration: By centralizing these non-opioid treatments, Viatris creates a one-stop-shop for hospital procurement departments. This could streamline the adoption process for hospitals looking to implement "opioid-sparing" protocols, as they will now be negotiating with a single, large-scale supplier.
2. The Patent Cliff Challenge: The primary risk remains the litigation surrounding Exparel. While the 2044 protection date is a strong shield, the fact that two other manufacturers are actively challenging these patents suggests that Viatris will need to be aggressive in its legal defense. The company’s history of managing generic and branded portfolios suggests it is well-equipped for this, but the risk of litigation impacting revenue remains non-zero.
3. Future Growth Prospects: With the potential approval of a fast-acting meloxicam on the horizon, Viatris is building a "pain franchise" that covers the spectrum of acute and chronic care. If the FDA grants approval in December, Viatris will effectively own a suite of products that covers patients from the operating table to the outpatient clinic for osteoarthritis.
4. Financial Outlook: For investors, the deal represents a shift toward predictability. In a market where high-growth biotech stocks often see extreme volatility, Viatris is signaling that it prefers the steady, predictable cash flows generated by mature, high-barrier-to-entry medical products. While this may not result in explosive stock price growth, it provides a defensive hedge against the broader market’s susceptibility to regulatory and R&D setbacks.
In conclusion, the acquisition of Pacira’s pain assets is a calculated move by Viatris to consolidate its influence in a critical therapeutic area. By balancing the long-term potential of Exparel with the near-term cash flows of the existing portfolio, Viatris is doubling down on its identity as a powerhouse of commercial execution. As the company prepares for its late-year FDA decision, all eyes will be on whether this strategy of "purchasing on-market" can continue to deliver the margin expansion that shareholders have come to expect.
About the Author
